CLINICAL SIGNIFICANCE OF DETERMINING THE LEVEL OF THE BRAIN NATRIURETIC PEPTIDE FOR THE DIAGNOSIS OF HEART FAILURE OF COMORBID PATIENTS WITH CORONARY HEART DISEASE AND THYROTOXICOSIS

Aim: To evaluate clinical significance of determining the level of the brain natriuretic peptide for the diagnosis of heart failure of comorbid patients with coronary heart disease and thyrotoxicosis. Materials and methods: 111 patients aged 45 to 65 years (average age was 58.3 ± 5.6 years) were included in the research. All the patients were divided into 4 groups: the main one consisted of 25 patients with thyrotoxicosis, coronary heart disease (CHD) and II-III functional class (FC) chronic heart failure (CHF); the 1st comparison group consisted of 30 patients with coronary heart disease and II -III FC CHF, but without thyroid dysfunction; the 2nd comparison group consisted of 30 patients with thyrotoxicosis without CHD; the 3rd comparison group consisted of 26 patients with thyrotoxicosis and coronary heart disease, without CHF. The following research methods were used in the work: the clinical state assessment scale (CSAS), the 6-minute walk test (6MWT), echocardiography. The level of the N-terminal pro-B-type natriuretic peptide (NT-proBNP) was determined using laboratory sets for enzyme immunoassay (Biomedica, Austria). Results: The comparative analysis of the CSAS indices did not reveal a significant difference in the severity of the clinical symptoms of CHF for the patients of the primary and the 1st comparison group (7.08 and 6.61, respectively, p> 0.05). At the same time, tolerance to physical activity for the patients of the main group was 1.2 times lower than for the patients of the 1st comparison group (p = 0.01). The contractility of left ventricular myocardium for the patients of the main group was significantly lower, as evidenced by the lowest left ventricular ejection fraction — 40.0 (37.0, 42.0)% (compared to patients of all comparison groups, p <0.001). The level of NT-proBNP was increased in all compared groups, including the patients with thyrotoxicosis without combining with IHD and CHF. The values of this index for patients with IHD and CHF and for patients with IHD and thyrotoxicosis without CHF did not differ significantly. The highest concentration of NT-proBNP was obtained in a group of patients with a combination of thyrotoxicosis, coronary heart disease and CHF (p <0.05). The hyperfunction of the thyroid body (gland), apparently, has a stimulating effect on the secretion of natriuretic peptides as the early marker of CHF. Conclusions: At comorbid patients with a thyrotoxicosis and an ischemic heart disease in the conditions of clinically expressed CHF the highest NT-proBNP level, apparently, is caused by influence on production of a natriuretic peptide both hyperfunction of a thyroid gland, and restructuring and a dilatation of cavities of heart, which dictates the need to revise the threshold values of serological markers for the timely diagnosis of heart failure and optimize the maintenance of this category of patients.

natriuretic peptide, coronary heart desease, chronic heart failure, thyrotoxicosis, comorbid patients

1. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. и соавт. Истинная распространенность ХСН в Европейской части Российской Федерации (исследование ЭПОХА, госпитальный этап). Сердечная недостаточность. 2011; 12 (2): 63-68. Belenkov Yu.N., Mareev V.Yu., Ageev F.T. et al. Veritable prevalence of CHF in the European part of Russia (EPOCHA trial, Hospital stage). Heart failure. 2011; 12(2): 63-68 [in Russian].

2. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность. 2013; 14(7). National recommendations of OSSN, RKO and RNMOT on diagnosis and treatment of CHF (fourth revision). Heart failure. 2013; 14(7) [in Russian].

3. Фролова Э.Б., Яушев М.Ф. Современное представление о хронической сердечной недостаточности. Вестник современной клинической медицины. 2013; 6(2): 87-93. Frolova E.B., Yaushev M.F. Current understanding of Chroniс heart failure. The Bulletin of Contemporary Clinical Medicine. 2013; 6 (2):87-93. [in Russian]. DOI:10.20969/vskm.2013.6(2).87-93.

4. Fortin M., Bravo G. Prevalence of Multimorbidity Among Adults Seen in Family Practice. Annals of Family Medicine. 2005; 3(3): 223- 228. DOI: 10.1370/afm.272

5. Шульгина В.Ю., Фадеев В.В., Мельниченко Г.А. Поражение миокарда при тиреотоксикозе: особенности течения, исходы, отдаленный прогноз. Клиническая и экспериментальная тирео идология. 2006; 2(4): 21-30. Shulgina V.Y., Fadeyev V., Melnichenko G. Myocardial lesion in hyperthyroidism: natural history, outcomes, prognosis. Clinical and experimental thyroidology. 2006; 2(4):21-30. [in Russian]. DOI:10.14341/ket20062421-30

6. Ponikowski P., A. Voors A., D. Anker S., Bueno H., G. F. Cleland J., J. S . Coats A., Falk V., González-Juanatey J., Harjola V., A. Jankowska E., Jessup M., Linde C., Nihoyannopoulos P., T . Parissis J., Pieske B., P. Riley J., M. C. Rosano G., M. Ruilope L., Ruschitzka F., H. Rutten F., van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)

7. Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J (2016), 37: 2129-2200. DOI:10.1093/eurheartj/ehw128

8. Ponikowski P., A. Voors A., D. Anker S., Bueno H., G. F. Cleland J., J. S . Coats A., Falk V., González-Juanatey J., Harjola V., A. Jankowska E., Jessup M., Linde C., Nihoyannopoulos P., T. Parissis J., Pieske B., P. Riley J., M. C. Rosano G., M. Ruilope L., Ruschitzka F., H. Rutten F., van der Meer P. Рекомендации ESC по диагностике и лечению острой и хронической сердечной недостаточности 2016. Российский кардиологический журнал. 2017; (1): 7-81. DOI:10.15829/1560-4071-2017-1-7-81 Ponikowski P., A. Voors A., D. Anker S., Bueno H., G. F. Cleland J., J. S . Coats A., Falk V., González-Juanatey J., Harjola V., A. Jankowska E., Jessup M., Linde C., Nihoyannopoulos P., T. Parissis J., Pieske B., P. Riley J., M. C. Rosano G., M. Ruilope L., Ruschitzka F., H. Rutten F., van der Meer P. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Russian Journal of Cardiology. 2017; (1): 7-81. [in Russian]. DOI: 10.15829/1560- 4071-2017-1-7-81

9. Голухова Е.З., Алиева А.М. Клиническое значение определения натрийуретических пептидов у больных с хронической сердечной недостаточностью. Кардиология и сердечно-сосудистая хирургия. 2007; 1: 45-51. Golukhova E.Z., Alieva A.M. Clinical value of natriuretic peptides detection at the patients with chronic heart failure. 2007; 1: 45-51 [in Russian].

10. DeFilippi C.R., Christenson R.H. , Gottdiener J.S. et al. Dynamic cardiovascular risk assessment in the elderly: The role of repeated amino terminal pro-B-type natriuretic peptide testing. J Am Coll Cardiol. 2010; 55(5): 441–450. DOI: 10.1016/j. jacc.2009.07.069

11. Ozmen B., Ozmen D., Parildar Z. et al. Serum N-terminal-pro-Btype Natriuretic Peptide (NT-pro-BNP) levels in hyperthyroidism and hypothyroidism. Journal Endocr. Res. 2007; 32(1-2): 1-8.

12. Ertugrul D.T., Gursoy A., Sahin M. et al. Evaluation of Brain Natriuretic Peptide Levels in Hyperthyroidism and Hypothyroidism. Journal of the National Medical Association. 2008; 100(4): 401- 405. DOI: 10.1016/S0027-9684(15)31272-4.

13. Kato K., Murakami H. et al. Serum concentrations of BNP and ANP in patients with thyrotoxicosis. Endocrine Journal. 2009; 56 (1): 17-27. DOI: 10.1507/endocrj.k08e-145

14. Pakuła D., Marek B., Kajdaniuk D. Plasma levels of NT-probrain natriuretic peptide in patients with overt and subclinical hyperthyroidism and hypothyroidism. Endokrynol Pol. 2011; 62(6): 523-528.

15. Schultz M., Faber J. еt al. N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states. Clin Endocrinol (Oxf). — 2004; 60(1): 54-9. DOI: 10.1111/j.1365-2265.2004.01941.x

16. SenayArikan, AlpaslanTuzcu, DenizGokalpet al. Hyperthyroidism may affect serum N-terminal pro-B-type natriuretic peptide levels independently of cardiac dysfunction. Clinical Endocrinology. 2007; 67 (2): 202-207. DOI: 10.1111/j.1365-2265.2007.02861.x

17. Huang Chenggang, Chen Xiaoyanet al.Value of the NT-ProBNP in ~(131)I-Treating Patients with Hyperthyroid and Thyrotoxic Heart Disease. Chinese Journal of Microcirculation. 2009; 2.

18. Xiaoping Li, Xinwei Yang et al. The Prevalence and Prognostic Effects of Subclinical Thyroid Dysfunction in Dilated Cardiomyopathy Patients: A Single-Center Cohort Study. Journal of Cardiac Failure. 2014; 20 (7): 506-512. DOI:10.1016/j. cardfail.2014.05.002

19. Карась А.С., Обрезан А.Г. Щитовидная железа и сердце. Клиническая и экспериментальная тиреоидология. 2009; 5(3): 37-42. Karas A., Obrezan A. Thyroid and the Heart. Clinical and experimental thyroidology. 2009; 5(3): 37-42 [in Russian].

20. Гома Т.В., Хамнуева Л.Ю., Орлова Г.М. Поражение сердечно- сосудистой системы при тиреотоксикозе. Сибирский медицинский журнал. 2007; 3: 9-12. Goma T.V., Chamnueva L.Yu., Orlova G.M. The affection of cardiovascular system in hyperthyroidism. Siberian Medical Journal. 2007; 3: 9-12 [in Russian].

21. Galli E., Pingitore A., Iervasi G. The role of thyroid hormone in the pathophysiology of heart failure: clinical evidence. Heart Failure Reviews 2010; 15: 155–169. DOI:10.1007/s10741-008-9126-6.

22. Biondi B., Kahaly G.J. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nature Review Endocrinology. 2010; 6: 431–443. DOI:10.1038/nrendo.2010.105.

23. Biondi B. Mechanisms in endocrinology: Heart failure and thyroid dysfunction. Eur J Endocrinol. 2012; 167(5): 609-618. DOI: 10.1530 / EJE-12-0627.

24. Ozmen B., Ozmen D., Parildar Z. et al. Serum N-terminal-pro-Btype Natriuretic Peptide (NT-pro-BNP) levels in hyperthyroidism and hypothyroidism. Journal Endocr. Res. 2007; 32(1-2): 1-8.

25. Pakuła D., Marek B., Kajdaniuk D. Plasma levels of NT-probrain natriuretic peptide in patients with overt and subclinical hyperthyroidism and hypothyroidism. Endokrynol Pol. 2011; 62(6): 523-528.

26. Biondi B., Kahaly G.J. The сardiovascular risk in thyroid dysfunction. Thyroid international. 2013; 3: 2-8.